What is the Oncotype DX test?
The Oncotype DX test is a type of genomic test that will allow the doctors to better understand how likely an estrogen receptive cancer is to come back (recurrence) and how it will respond to different types of chemotherapy medicines.
Once these results are back, the oncologist may decide to alter the treatment plan (shorter duration of treatment (3 months) and fewer chemo meds administered), or he/she may decide to move forward with the original chemotherapy schedule.
In my case, my Oconotype Dx score ended up being very low, meaning that my risk for recurrence is also low. Based on the other factors (size of tumor, micrometastases to a lymph node) the tumor board unanimously recommended TC x 4 chemotherapy, and my oncologist concurred.
All in all, that meant that I would receive 4 rounds of chemotherapy with Taxotere and Cyclophosphamide (given together) administered through the port that was placed in a couple weeks prior.
The 4 treatments (or chemotherapy sessions) were to be administered 3 weeks apart. After the conclusion of the 4 rounds of chemotherapy I would start radiation.
